Wuhan YZY Biopharma Secures FDA IND Approval for M701 in MPE: CYMB

[Para 1: The Lead] Wuhan YZY Biopharma (CYMB:WSH) secures FDA Investigational New Drug (IND) clearance for its M701 drug in Middle East Respiratory Syndrome (MPE) treatment, marking a pivotal step in advancing the company's biopharmaceuticals. The approval is effective as of February 3, 2026, enabling clinical trials to proceed without delay. [Para 2-3: Supporting details & Context] The FDA's IND clearance for M701 is based on preliminary clinical and preclinical data demonstrating safety and efficacy in treating MPE. The drug is expected to compete in a market projected to grow significantly with the increasing prevalence of MPE globally. Wuhan YZY Biopharma aims to enroll 100 patients in the Phase II trial, with an estimated completion date of Q3 2026. Financial highlights include a $50 million funding round in Q4 2025 to support clinical development and manufacturing.